Article
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
The Lancet. Oncology - 1 Dec 2021
Fischer Matthias, Moreno Lucas, Ziegler David S, Marshall Lynley V, Zwaan C Michel, Irwin Meredith S, Casanova Michela, Sabado Constantino, Wulff Beate, Stegert Mario, Wang Luojun, Hurtado Felipe K, Branle Fabrice, Geoerger Birgit, Schulte Johannes H
Abstract excerpt
BACKGROUND: Several paediatric malignancies, including anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumour (IMT), neuroblastoma, and rhabdomyosarcoma, harbour activation of anaplastic lymphoma kinase (ALK) through different mechanisms. Here, we report the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. METHODS: This multicentre,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.